Oral bisphosphonates for osteoporosis in adult males with intellectual disabilities

J Appl Res Intellect Disabil. 2021 May;34(3):921-925. doi: 10.1111/jar.12862. Epub 2021 Feb 4.

Abstract

Introduction: Oral bisphosphonates are first-line agents for treating osteoporosis in men, but there are no studies regarding efficacy of oral bisphosphonates for treatment of osteoporosis in ambulatory male adults with intellectual disability.

Methods: Nine adult males with intellectual disability and increased fracture risk had been treated with weekly or monthly oral bisphosphonates, vitamin D and calcium for 1-3 years. Post-treatment bone mineral density (BMD), serum 25(OH)D, parathyroid hormone and C-telopeptide of type I collagen were then determined for the first time.

Results: Weekly or monthly oral bisphosphonates were well tolerated and led to significant increases in BMD in all 9 individuals. Serum 25(OH)D level enhanced the "pecent increase of BMD" that occurred in response to bisphosphonate treatment (p < .05).

Conclusions: Weekly or monthly oral bisphosphonates are well tolerated by ambulatory adult males with ID and are effective in increasing BMD. Higher serum levels of vitamin D appear to improve the efficacy of bisphosphonates and therefore reduce fracture risk in adult males with intellectual disability.

Keywords: bisphosphonates; intellectual disability; osteoporosis; vitamin D.

MeSH terms

  • Adult
  • Bone Density
  • Bone Density Conservation Agents*
  • Diphosphonates
  • Humans
  • Intellectual Disability* / complications
  • Intellectual Disability* / drug therapy
  • Male
  • Osteoporosis* / drug therapy

Substances

  • Bone Density Conservation Agents
  • Diphosphonates